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Objectives: the preventive effect of acetylsalicylic acid in cardiovascular disease may be due to inhibition of platelet
aggregation mediated by COX-1, but may in addition be due to anti-inflammatory effects by inhibition of COX-2. The
objective of this study was to analyse the expression of COX-1 and COX-2 in atherosclerotic and healthy vascular walls.
Design: the expression COX-1 and COX-2 was analysed in biopsies from human atherosclerotic carotid arteries and
from healthy mammary arteries and saphenous veins.
Materials: vascular biopsies were obtained from patients undergoing carotid endarterectomy or coronary bypass surgery.
Methods: RT-PCR was used for mRNA analysis and for localization of proteins we used immunohistochemistry.
Results: COX-2 was found in atherosclerotic plaques: in macrophages, in some smooth muscle cells and in endothelial
cells of small vessels in the lesions. In non-atherosclerotic blood vessels, COX-2 was detected in the endothelium of the
vasa vasorum in the adventitia. COX-1 was found in the endothelium in healthy and in atherosclerotic vessels.
Conclusions: the expression of COX-2 by inflammatory and vascular cells in atherosclerotic arteries suggests that
products of this enzyme may be important in the pathogenesis of atherosclerosis.
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Introduction consitutively expressed by the vascular endothelium,
platelets, kidneys, and elsewhere.11 In addition, a cy-
Several lines of evidence implicate immune and in- tokine-inducible cyclo-oxygenase, COX-2, has been
flammatory mechanisms in the pathogenesis of athero- detected in several different cell types.12–14 The ex-
sclerosis. Human atherosclerotic plaques contain large pression of COX-2 is restricted under basal conditions
numbers of macrophages and also significant amounts and upregulated during inflammation, e.g. in rheum-
of T lymphocytes, many of which are in an activated atoid arthritis.15 Expression of COX-2 in human um-
state.1–3 Activated immune cells secrete a host of cyto- bilical vein endothelial cells is stimulated by
kines, which regulate gene expression in other cells of inflammatory mediators like tumour necrosis factor-
the plaque by paracrine action.4 In atherosclerosis,  interleukin-116 and by hypoxia.17 This provides a
much interest has been focused on cytokine-regulated synthetic pathway for eicosanoids which is regulated
expression of metalloproteinases,5 MHC genes,6 actins7 in an entirely different way from the constitutive one
and collagens8 and its possible role in the progression and directly lined to inflammation.18
of atherosclerosis4 and the development of acute cor- Acetylsalicylic acid (ASA), an inhibitor of both COX-
onary syndromes.9 1 and COX-2, has been used for several years as
In addition to cytokines and growth factors, non- primary and secondary prophylactic drugs in cardio-
protein mediators also play pivotal roles in the re- vascular disease.19 The beneficial effect of ASA – a
gulation of vascular function. For instance, prosta- traditional anti-inflammatory drug – has previously
glandins E2 (PGE2) and PGI2 are important modulators been linked to its effects on platelets.20 Inhibition of
of lipid metabolism, vascular cell proliferation, and cyclo-oxygenases in platelets by ASA blocks the path-
platelet aggregation.10 They are normally produced way leading to thromboxane formation and platelet
by the enzyme cyclo-oxygenase-1 (COX-1), which is
aggregation is thus prevented. Recent evidence sug-
gests that the preventive effect of ASA in cardio-
∗ Please address all correspondence to: V. Stemme, Cardiovascular vascular disease may also be linked to its anti-Research Unit, Center for Molecular Medicine, L8:03, Karolinska
Hospital, S-171 76 Stockholm, Sweden. inflammatory properties.21
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Since inflammation is an integral part of athero- GmbH, Mannheim, Germany) in 30 cycles of 94 °C for
1 min, 58 °C for 1 min, 72 °C for 1 min, and after thesclerosis and the preventive effect of ASA may, at least
partially, be due to its anti-inflammatory effect, it is last cycle a 10 min elongation step at 72 °C. The PCR-
products were then visualised in ethidium-bromideof interest to establish whether COX-2 is present in
atherosclerotic lesions. In the present study we ana- stained 1.5% agarose gels, using a 100 bp DNA ladder
(Gibco BRL, Life Technologies, Gaithersburg, MD,lyzed the expression of COX-1 and COX-2, mRNA
and protein, in human carotid atherosclerotic arteries U.S.A.) as a size marker.
The following primers were used:24and in non-atherosclerotic mammary arteries and sa-
phenous veins. COX-1: 5′-CCT ACA CCT CCT TCC AGG AGC TC-3′
5′-AGA CCA GCT TCT TCA GTG TGG CCG-3′
COX-2: 5′-TTC AAA TGA GAT TGT GGG AAA ATT
GCT-3′
Materials and Methods 5′-AGA TCA TCT CTG CCT GAG TAT CTT-3′
Vascular biopsies
Immunohistochemistry
Specimens from atherosclerotic carotid arteries were
obtained from symptomatic patients undergoing ca- The tissue sections were fixed for 5 min in acetone in
rotid endarterectomy. Specimens from non-athero- room temperature, rinsed in PBS and air-dried. The
sclerotic arteries (mammary artery) and veins sections were preincubated in 5% Normal Goat Serum
(saphenous vein) were obtained from patients under- (NGS) and 2% dry milk powder at room temperature
going coronary bypass surgery. The tissue biopsies for 30 min. Incubation with primary antibodies in 1%
were divided in two to four pieces. Samples for bovine serum albumin (BSA, Sigma Chemical Co, St.
immunohistochemistry were embedded in Tissue-Tek Louis, MO, U.S.A.) and 2% dry milk powder were
O.C.T. Compound (Miles Inc. Diagnostics Division, performed at 4 °C over night. The optimal con-
Elkhart, IN, U.S.A.), snap frozen in liquid nitrogen and centration for each antibody was established by serial
stored at −80 °C. Cryostat sections from the vascular dilution experiments on carotid endarterectomy speci-
biopsies were cut and mounted on SuperFrostPlus mens and on cultured human macrophages stimulated
glass slides (Menzel-Gla¨ser, Germany) and sections by lipopolysaccharide. After rinsing with PBS, the
stored at−80 °C. For RNA extraction, tissue specimens sections were incubated with secondary antibodies in
were frozen immediately in liquid nitrogen and stored 1% BSA and 2% dry milk powder at room temperature
at −80 °C. for 30 min. After incubation with ABC-AP (Avidin–
Biotin Complex Alkaline Phosphatase, Vector Laborat-
ories, Burlingame, CA, U.S.A.) or PAP (Peroxidase
Anti-Peroxidase, DAKO A/S, Glostrup, Denmark)
RNA-extraction and RT-PCR staining procedures were performed with alkaline
phosphatase (Alkaline Phosphatase Substrate Kit, Vec-
RNA-isolation from the tissue biopsies was performed tor Laboratories) or peroxidase (Peroxidase Substrate
using ULTRASPECTM RNA isolation system (Biotecx Kit, Vector Laboratories) according to the manu-
Laboratories, Inc., Houston, TX, U.S.A.) and the RNA- facturer’s instructions. The sections were counter-
samples were then analysed by reverse transcriptase stained with Haematoxylin Harris stain solution at
polymerase chain reaction (RT-PCR) technique.22,23 room temperature for 15 s (Histolab Products AB,
cDNA synthesis was performed from 1 g total RNA Go¨teborg, Sweden). Microphotographs were taken
per sample in 20 l of 50 mM Tris-HCl, pH 8.3, 75 mM using a Leica DMRB microscope with a WILD MPS48
KCl, 3 mm MgCl2, 50 pmol pd(N)6 (Pharmacia Biotech, photo unit (Leica Mikroskopie und Systeme GmbH,
Uppsala, Sweden), 1 mM dNTP, 10 mm dithiothreitol Wetzlar, Germany). The film used was Kodak GOLD,
(DTT), 200 units Superscript II Reverse Transcriptase 200 ASA (Eastman KODAK Company, Rochester, NY,
(Stratagene, La Jolla, CA, U.S.A.) in 42 °C for 50 min U.S.A.).
followed by inactivation of the reverse transcriptase
in 70 °C for 15 min. Five microlitres from each cDNA
reaction were used for PCR amplification in 10 mm Antibodies
Tris-HCl, pH 8.3, 1.5 mm MgCl2, 50 mm KCl, 0.2 mm
dNTP, 50 pmol of each oligonucleotide primer, 1.25 The following primary antibodies were used:
Anti-COX-1 (polyclonal rabbit anti-human COX-1)units of Taq DNA polymerase (Boehringer Mannheim
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Immunohistochemistry analysis showed that COX-
2 as well as COX-1 proteins were expressed in sections
from atherosclerotic arteries. Ten plaques from dif-
ferent patients were analysed. COX-2 was detected in
macrophages as revealed by double-staining using
anti-COX-2 together with the macrophage-specific
marker, CD68 (Fig. 2). COX-2 was particularly abund-
ant in macrophages in and close to the necrotic parts
of the atherosclerotic lesion. Using anti-COX-2 together
with anti-von Willebrand factor, we also detected COX-
Fig. 1. Analysis by RT-PCR of mRNA for COX-1 and COX-2 in 2 in endothelial cells in small blood vessels in the
human atherosclerotic carotid arteries. The picture shows four rep- lesion and in sparse parts of the luminal endotheliumresentative samples of nine plaques analysed. The expected sizes
(data not shown). COX-1 protein was detected in intactof the RT-PCR-products are 285 bp (COX-1) and 305 bp (COX-2)
respectively. Lanes 1–4: RT-PCR-products for COX-1. Lanes 5–8: RT- parts of the endothelium (Fig. 2). Finally, staining for
PCR-products for COX-2. COX-2 could be detected in some SM-actin positive
smooth muscle cells in the thickened intima and inand anti-COX-2 (polyclonal rabbit anti-human COX-
the media under the plaque (Fig. 2).2) was kindly provided by A. W. Ford-Hutchinson,
Merck Frost Centre for Therapeutic Research (Quebec,
Canada). The antibodies have approximately 1000-fold
selectivity for COX-1 and COX-2 respectively.25
Anti-SM-actin (to identify smooth muscle cells): Cyclo-oxygenase expression in non-atherosclerotic vessels
monoclonal mouse anti-human SM-actin (DAKO A/
S). The expression of COX-2 and COX-1 in human mam-
Anti-von Willebrand Factor (to identify endothelial mary arteries, with no macroscopic signs of athero-
cells): monoclonal mouse anti-human von Willebrand sclerosis, and in saphenous veins was examined by
Factor (DAKO A/S). RT-PCR and immunohistochemistry. COX-2 mRNA
Anti-CD 68 (to identify macrophages): monoclonal was detected in four out of five mammary arteries
mouse anti-human CD 68 (DAKO A/S). and in four of four saphenous veins (Fig. 3). COX-1
As secondary antibodies we used: (i) biotinylated mRNA was detected in all analysed mammary arteries
goat anti-rabbit (Vector Laboratories) for polyclonal and saphenous veins (Fig. 3).
primary antibodies and (ii) rabbit anti-mouse immuno- In both the mammary arteries (Fig. 4) and the sa-
globulins (DAKO A/S) for monoclonal primary anti- phenous veins (data not shown), COX-2 protein was
bodies. detected in the vasa vasorum in the adventitia by
immunohistochemistry. Sparse staining for COX-2 was
also detected in some parts of the endothelium (data
not shown). COX-1 protein was detected in the luminalResults
endothelium in the mammary arteries (Fig. 4) as well
as in the saphenous veins (data not shown).Specimens of human vascular tissue were collected
at surgery and immediately prepared for analysis.
Atherosclerotic plaques were obtained from carotid
arteries at endarterectomy and normal mammary ar-
teries and saphenous veins at coronary bypass surgery. Discussion
Gene expression was analysed on the mRNA level
using PCR after reverse transcription into cDNA (RT- In the present study we report the expression of COX-
PCR) and on the protein level by immuno- 2 in atherosclerotic lesions. The presence of COX-2 has
histochemistry. been described in other conditions in which in-
flammation is part of the pathological process, e.g.
in synovial tissue in rheumatoid arthritis.26 Under
physiological conditions, COX-1 catalyses the rate-Cyclo-oxygenase expression in atherosclerotic arteries
limiting step in the synthesis of prostaglandins, e.g.
PGI2 in the endothelium, leading to vasodilatation andRT-PCR analysis demonstrated expression of COX-2
mRNA in all (nine) atherosclerotic arteries, while COX- counteracting platelet aggregation. A protective role
has been proposed for COX-2, by mediating release1 mRNA was detected in four of nine (Fig. 1).
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Fig. 2. Immunohistochemical analysis of COX-2 and COX-1 protein in human atherosclerotic carotid arteries. (A) COX-2 staining (alkaline
phosphatase, red) in the atherosclerotic lesion and in the media under the lesion. Original magnification: 5×. (B) Negative control with
no primary antibody, original magnification: 5×. (C) Double staining for COX-2 (alkaline phosphatase, red) and CD 68, a macrophage-
marker (peroxidase, brown staining), in the shoulder region of the plaque. Original magnification: 10×. (D) Double staining for COX-2
and -actin, as marker for smooth muscle cells (peroxidase, brown staining), in the thickened intima adjacent to the necrotic core. Original
magnification: 20×. (E) Double staining for COX-1 (alkaline phosphatase, red) and von Willebrand Factor, as a marker for endothelial
cells (peroxidase, brown staining), in the luminal endothelium. Original magnification: 40×.
of PGI2, in conditions where the endothelium is dam- COX-2 has been found in activated smooth muscle
cells after vascular injury in rat arteries,28 indicating aaged or dysfunctional.27 On the other hand, prosta-
glandins also mediate inflammatory reactions. The role for COX-2 in the development of intimal hy-
perplasia. COX-2 has also been detected in culturedactivity of COX-2 is induced by inflammatory cyto-
kines and cyclo-oxygenases catalyse the synthesis of smooth muscle cells after stimulation with interleukin-
1, tumour necrosis factor-, interferon-, and bacterialthromboxane, e.g. TXA2, leading to vasoconstriction
and platelet aggregation. lipopolysaccharide.29 Induction of COX-2 has been
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DNA synthesis in smooth muscle cells31 and it is
therefore possible that COX-2 activity in vascular
smooth muscle cells and macrophages may result
in an autocrine or paracrine growth-promoting loop.
Furthermore, the COX-2 products, PGE2 and PGI2,
may reduce cholesterol accumulation by inhibiting
neutral cholesterol ester hydrolase and other chol-
esteryl ester cycle enzymes10 and in the case of PGI2
inhibit platelet adhesion to the arterial wall.11 Finally,
they may regulate the expression of proinflammatory
cytokines in the plaque by a negative feedback loop.10
The precise consequences of COX-2 expression de-
pend not only on the presence of the enzyme but
also on the substrate availability, i.e. the release ofFig. 3. Analysis by RT-PCR of mRNA for COX-1 and COX-2 in
arachidonic acid from phospholipids. The activation ofhuman mammary artery and saphenous vein. The picture shows
two representative samples from each vessel. The expected sizes phospholipases may therefore represent an additional
of the RT-PCR-products are 285 bp (COX-1) and 305 bp (COX-2) regulatory step in the prostaglandin synthesis of therespectively. Lanes 1, 2: RT-PCR-products for COX-1. Lanes 3, 4: RT-
atherosclerotic lesion. The extent of phospholipasePCR-products for COX-2. Lanes 5, 6: RT-PCR-products for COX-1.
Lanes 7, 8: RT-PCR-products for COX-2. activation, availability of archidonic acid, expression
of COX-2, downstream formation of eicosanoids may
differ depending on the microenvironment and maydemonstrated in human saphenous veins and mam-
result in the synthesis of different levels and differentmary arteries after stimulation with interleukin-1.27 In
species of prostaglandins. It may therefore be neces-human cerebral arteries COX-2 expression has been
sary to carry out blocking experiments before theshown after cerebral ischaemia, indicating a role for
consequences of COX-2 expression can be predicted.COX-2 in ischaemic injury in the human brain.30
ASA has a documented preventive effect againstThe present study shows that COX-2 is expressed
complications and symptoms in cardiovascular dis-in smooth muscle cells of the intimal layer of the
ease.19,20 This effect may be due to dual effects: in-human artery in atherosclerosis. The simultaneous
hibition of COX-1 in platelets preventing plateletexpression of proinflammatory cytokines in athero-
aggregation and an anti-inflammatory effect by in-sclerotic lesions suggests that these factors may induce
hibiting COX-2. It is tempting to speculate that in-COX-2 expression. The functional role of COX-2 ac-
hibition of an inflammatory reaction induced by COX-tivity is less obvious. However, several interesting
2 could be of importance to prevent the developmentpossibilities arise from cell biological studies. Thus,
prostaglandins, at picomolar concentrations, induce of atherosclerosis. Inhibition of COX-1, on the other
Fig. 4. Immunohistochemical analysis of COX-2 and COX-1 in human mammary artery. Alkaline phosphatase (red) was used for the
COX-2 and COX-1 stainings. (A) COX-2 staining in vasa vasorum in the adventitia, original magnification: 10×. (B) COX-1 staining in
the luminal endothelium, original magnification: 10×.
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